The Development and Application of a Monoclonal Antibody Purification Platform - A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the de


The Development and Application of a Monoclonal Antibody Purification Platform
A purification scheme to maximize the efficiency of the purification process and product purity while minimizing the development time for early-phase therapeutic antibodies.

BioPharm International Supplements

Performance Results

Table 1. Impurity profiles and classifications for various therapeutic monoclonal antibodies using the platform processes outlined in this article
Table 1 shows the impurity levels for various Pfizer antibodies using the processes outlined in Figure 1. The impurity profiles are collected after the final chromatography step. The percent monomer is determined by size exclusion high performance liquid chromatography, using two G3000 SWXL columns (Tosoh, Montgomeryville, PA) in series with detection of the antibody at 214 nm. HCP is detected using a high-sensitivity sandwich Enzyme-Linked ImmunoSorbent Assay (ELISA) kit specific for either CHO or NS0 proteins following the manufacturer's instructions (Cygnus Technologies, Southport, NC). We measured residual recombinant protein A levels using a sandwich ELISA kit from Repligen (Waltham, MA). Finally, residual total DNA was evaluated by extraction using the DNA extractor kit from Wako (Richmond, VA), followed by detection of the single-stranded DNA using a threshold kit (Molecular Devices, Sunnyvale, CA).

Figure 3. Graph of the log viral clearance values obtained for the therapeutic antibodies shown in Table 1. The changes in color correspond to the processes outlined in Figure 1. From left to right: original process, process 2, process 3, and current process.
The results indicate that for the representative antibodies shown for the different process permutations, the current purification scheme as outlined is sufficient to produce an acceptable product. A few of the antibodies required minor changes to the platform process to produce the desired product purity, as explained in Table 1. Figure 3 shows the overall virus reduction achieved for the early-phase representative antibodies in the different platform processes. Again, the results indicate that all processes achieved satisfactory viral clearance. However, the current process is advantageous as we increase column capacities to accommodate increasing titers, as insurance for acceptable virus clearance results.

Platform Status

The current process, as shown in Figure 1, provides Pfizer with a combination of purification and virus clearance robustness, allowing us to quickly move products into the pilot plant for clinical manufacturing, thus accelerating progress toward the clinic. Even though the other processes shown in Figure 1 also met these criteria, they did not meet our new standard for robustness established by increasing product titers. A process was needed that was more adept at handling changes in the composition of the cell culture broth as well as unexpected increases in titer following scale-up, requiring additional column capacities. Although the current process bucks the trend of reducing the number of unit operations, it increases the chance of meeting the purification needs of a greater number of projects in a shorter time frame. These early-phase purification processes can be optimized further once proof of concept has been achieved.

Next Steps

As cell culture titers continue to increase, the biopharmaceuticals industry will be faced with new challenges, including greater product heterogeneity and increasing impurity levels. As scale increases for early-phase manufacturing, resin capacity must increase to minimize operating costs, and therefore, it will be necessary to carry out studies to determine the impact of these changes on virus clearance and the removal of impurities. If increased capacity cannot meet these needs, alternative separation methods such as simulated moving bed chromatography will become paramount.

It also will become necessary to increase the throughput of nanofiltration devices, so that they do not become the next process bottleneck. In addition, we must develop new technologies for ultrafiltration to meet the need for high-concentration drugs used for subcutaneous injection. These are just some of the challenges facing the industry today.

blog comments powered by Disqus



GPhA Issues Statement on Generic Drug Costs
November 20, 2014
Amgen Opens Single-Use Manufacturing Plant in Singapore
November 20, 2014
Manufacturing Issues Crucial to Combating Ebola
November 20, 2014
FDA Requests Comments on Generic Drug Submission Criteria
November 20, 2014
USP Joins Chinese Pharmacopoeia Commission for Annual Science Meeting
November 20, 2014
Author Guidelines
Source: BioPharm International Supplements,
Click here